- Home
- ANIP
as 05-16-2025 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $80.13 | AVG Volume (30 days): | 472.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $73.72 | Next Earning Date: | 05-09-2025 |
| Revenue: | $674,068,000 | Revenue Growth: | 30.27% |
| Revenue Growth (this year): | 27.77% | Revenue Growth (next year): | 7.88% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | May 13 '25 | Sell | $62.20 | 400 | $24,880.00 | 79,745 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 9 '25 | Sell | $76.83 | 700 | $53,781.00 | 631,920 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Apr 14 '25 | Sell | $68.96 | 400 | $27,584.00 | 79,745 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Mar 19 '25 | Sell | $65.00 | 1,866 | $121,290.00 | 64,659 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Mar 13 '25 | Sell | $63.33 | 400 | $25,332.00 | 79,745 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Mar 7 '25 | Sell | $60.86 | 1,000 | $60,860.00 | 64,659 | |
| Gutwerg Ori | ANIP | SVP, GENERICS | Mar 5 '25 | Sell | $60.02 | 5,384 | $323,049.00 | 94,092 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Feb 21 '25 | Sell | $60.20 | 1,000 | $60,200.00 | 64,659 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
StockStory
6 days ago
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Argus Research
6 days ago
ANIP: Lowering target price to $65.00
StockStory
7 days ago
3 Small-Cap Stocks Walking a Fine Line
GlobeNewswire
7 days ago
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
Zacks
7 days ago
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Simply Wall St.
9 days ago
ANI Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
10 days ago
ANI Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Benzinga
10 days ago
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.